268 related articles for article (PubMed ID: 24378252)
1. An ELISA assay with two monoclonal antibodies allows the estimation of free factor H and identifies patients with acquired deficiency of this complement regulator.
Nozal P; Garrido S; Alba-Domínguez M; Espinosa L; Peña A; Córdoba SR; Sánchez-Corral P; López-Trascasa M
Mol Immunol; 2014 Apr; 58(2):194-200. PubMed ID: 24378252
[TBL] [Abstract][Full Text] [Related]
2. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome.
Dragon-Durey MA; Blanc C; Marliot F; Loirat C; Blouin J; Sautes-Fridman C; Fridman WH; Frémeaux-Bacchi V
J Med Genet; 2009 Jul; 46(7):447-50. PubMed ID: 19435718
[TBL] [Abstract][Full Text] [Related]
3. Functional evaluation of factor H genetic and acquired abnormalities: application for atypical hemolytic uremic syndrome (aHUS).
Roumenina LT; Roquigny R; Blanc C; Poulain N; Ngo S; Dragon-Durey MA; Frémeaux-Bacchi V
Methods Mol Biol; 2014; 1100():237-47. PubMed ID: 24218264
[TBL] [Abstract][Full Text] [Related]
4. Standardisation of the factor H autoantibody assay.
Watson R; Lindner S; Bordereau P; Hunze EM; Tak F; Ngo S; Zipfel PF; Skerka C; Dragon-Durey MA; Marchbank KJ
Immunobiology; 2014 Jan; 219(1):9-16. PubMed ID: 23891327
[TBL] [Abstract][Full Text] [Related]
5. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation.
Nilsson SC; Karpman D; Vaziri-Sani F; Kristoffersson AC; Salomon R; Provot F; Fremeaux-Bacchi V; Trouw LA; Blom AM
Mol Immunol; 2007 Mar; 44(8):1835-44. PubMed ID: 17084897
[TBL] [Abstract][Full Text] [Related]
6. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases.
Blanc C; Togarsimalemath SK; Chauvet S; Le Quintrec M; Moulin B; Buchler M; Jokiranta TS; Roumenina LT; Fremeaux-Bacchi V; Dragon-Durey MA
J Immunol; 2015 Jun; 194(11):5129-38. PubMed ID: 25917093
[TBL] [Abstract][Full Text] [Related]
7. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.
Józsi M; Strobel S; Dahse HM; Liu WS; Hoyer PF; Oppermann M; Skerka C; Zipfel PF
Blood; 2007 Sep; 110(5):1516-8. PubMed ID: 17495132
[TBL] [Abstract][Full Text] [Related]
8. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome.
Blanc C; Roumenina LT; Ashraf Y; Hyvärinen S; Sethi SK; Ranchin B; Niaudet P; Loirat C; Gulati A; Bagga A; Fridman WH; Sautès-Fridman C; Jokiranta TS; Frémeaux-Bacchi V; Dragon-Durey MA
J Immunol; 2012 Oct; 189(7):3528-37. PubMed ID: 22922817
[TBL] [Abstract][Full Text] [Related]
9. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome.
Strobel S; Hoyer PF; Mache CJ; Sulyok E; Liu WS; Richter H; Oppermann M; Zipfel PF; Józsi M
Nephrol Dial Transplant; 2010 Jan; 25(1):136-44. PubMed ID: 19666655
[TBL] [Abstract][Full Text] [Related]
10. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models.
Saunders RE; Abarrategui-Garrido C; Frémeaux-Bacchi V; Goicoechea de Jorge E; Goodship TH; López Trascasa M; Noris M; Ponce Castro IM; Remuzzi G; Rodríguez de Córdoba S; Sánchez-Corral P; Skerka C; Zipfel PF; Perkins SJ
Hum Mutat; 2007 Mar; 28(3):222-34. PubMed ID: 17089378
[TBL] [Abstract][Full Text] [Related]
11. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome.
Hofer J; Janecke AR; Zimmerhackl LB; Riedl M; Rosales A; Giner T; Cortina G; Haindl CJ; Petzelberger B; Pawlik M; Jeller V; Vester U; Gadner B; van Husen M; Moritz ML; Würzner R; Jungraithmayr T;
Clin J Am Soc Nephrol; 2013 Mar; 8(3):407-15. PubMed ID: 23243267
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies in haemolytic uraemic syndrome (HUS).
Skerka C; Józsi M; Zipfel PF; Dragon-Durey MA; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):227-32. PubMed ID: 19190803
[TBL] [Abstract][Full Text] [Related]
13. Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS).
Westra D; Volokhina E; van der Heijden E; Vos A; Huigen M; Jansen J; van Kaauwen E; van der Velden T; van de Kar N; van den Heuvel L
Nephrol Dial Transplant; 2010 Jul; 25(7):2195-202. PubMed ID: 20106822
[TBL] [Abstract][Full Text] [Related]
14. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome.
Abarrategui-Garrido C; Martínez-Barricarte R; López-Trascasa M; de Córdoba SR; Sánchez-Corral P
Blood; 2009 Nov; 114(19):4261-71. PubMed ID: 19745068
[TBL] [Abstract][Full Text] [Related]
15. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
Diamante Chiodini B; Davin JC; Corazza F; Khaldi K; Dahan K; Ismaili K; Adams B
Pediatrics; 2014 Jun; 133(6):e1764-8. PubMed ID: 24843055
[TBL] [Abstract][Full Text] [Related]
16. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency.
Lee BH; Kwak SH; Shin JI; Lee SH; Choi HJ; Kang HG; Ha IS; Lee JS; Dragon-Durey MA; Choi Y; Cheong HI
Pediatr Res; 2009 Sep; 66(3):336-40. PubMed ID: 19531976
[TBL] [Abstract][Full Text] [Related]
17. Association among Complement Factor H Autoantibodies, Deletions of CFHR, and the Risk of Atypical Hemolytic Uremic Syndrome.
Jiang H; Fan MN; Yang M; Lu C; Zhang M; Liu XH; Ma L
Int J Environ Res Public Health; 2016 Dec; 13(12):. PubMed ID: 27929404
[TBL] [Abstract][Full Text] [Related]
18. Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome.
Foltyn Zadura A; Zipfel PF; Bokarewa MI; Sturfelt G; Jönsen A; Nilsson SC; Hillarp A; Saxne T; Trouw LA; Blom AM
Arthritis Res Ther; 2012 Aug; 14(4):R185. PubMed ID: 22894814
[TBL] [Abstract][Full Text] [Related]
19. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
[TBL] [Abstract][Full Text] [Related]
20. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.
Köse O; Zimmerhackl LB; Jungraithmayr T; Mache C; Nürnberger J
Semin Thromb Hemost; 2010 Sep; 36(6):669-72. PubMed ID: 20865644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
